• LOGIN
  • SUBSCRIBE
  • FREE E-Newsletter/Product Bulletins

Cath Lab Digest

  • Follow us on
  • Home
  • About Us
    • Privacy Policy/Copyright
    • About VDM
    • Editorial Board
    • Contact
  • Issues
    • Current Issue
    • Issue Archives
  • Multimedia
  • Editor's Update
  • Advertise
  • Reprints
  • Authors & Reviewers
    • Author Instructions
    • Submission Portal
    • Reviewers

Search

Extra-Coronary Pressure Gradient Assessment: Use of the pressure wire in peripheral, valvular, and congenital heart disease

  • Volume 2 - Issue 2 - March/April 2005
  • Posted on: 9/5/08
  • 0 Comments
  • 10966 reads
Author(s): 

Ted Feldman, MD

The measurement of translesional pressure gradients was an integral part of the development of coronary angioplasty. Gruentzig demonstrated a relationship between post-PTCA translesional gradient and the occurrence of both early complications and late restenosis in the 1980s.1 At that time, only fluid-filled catheter systems were used, and were limited by their bulk, lack of fidelity, and pressure damping in small catheter lumens. Intracoronary gradient assessment has been repopularized by the availability of 0.014” guidewire mounted pressure sensors. These devices have been available for a number of years, but their utility for pressure gradient measurement in a variety of extra-coronary settings is not widely appreciated. This paper will review some of the applications of gradient measurement with pressure wires for valvular, peripheral, and congenital cardiovascular diseases.

Renal Artery Stenosis
Renal artery translesional pressure gradients are used in practice for decision making about intervention for renal artery stenosis. A 20mm peak-to-peak pressure gradient between the aorta and distal renal artery is typically considered physiologically significant. There are no clear data to support this “magic number” for the determination of clinically important renal artery lesions, or to support this gradient “cut-off” as an indication intervention for renal artery stenosis. Despite the lack of evidence for a threshold value for important renal artery stenosis, pressure gradient measurement still has great utility in these cases. The absence of a gradient is useful in many cases. Monitoring changes in gradient during intervention is also useful.

Methods for Measurement: Figure 1 shows the most common method used to measure a renal artery origin lesion to obtain a translesional gradient. There is a 5 French diagnostic catheter placed into the renal orifice and then pulled back. This approach is limited by pressure damping, which may create the appearance of a gradient when none is present. It is easy to angle the catheter so it is either wedged in the lesion or damped against the wall of the vessel. A moderate lesion may appear hemodynamically severe.

Damping is only one of the artifacts to which pressure tracings are subject (Table 1). Most translesional gradient measurements are done using two fluid-filled systems. Many of the disposable pressure transducers in use today are subject to more drift than most of us realize. It is critical to zero and match both pressure systems in the aorta prior to measuring a gradient. For borderline measurements, reversing the transducers to verify a consistent gradient remains an important way to double-check the accuracy of the measurements.
Figure 2 shows the traditional method for double-pressure renal artery translesional pressure gradient assessment. A 6 Fr guide catheter is used to place a 4 Fr exchange type catheter distally in the renal artery. A distal contrast injection (lower right panel) confirms that the 4F catheter is well positioned. There is an acute angle where the guide meets the renal artery orifice, which may contribute to an unreliable distal pressure measurement.

As an alternative to two fluid-filled catheter systems, a pressure wire may be used. Figure 3 shows a case using a pressure wire to measure the translesional gradient. The stenosis is a non subtotal renal artery lesion. The patient is hypertensive, with a systemic systolic pressure that ranges between 170–200 mmHg. With the pressure wire passed through a diagnostic catheter, the peak-to-peak gradient is 15 to 20 mm Hg. The lesion is completely resolved with placement of a stent (lower panel).

Figure 4 shows a restenosis lesion in a previously placed renal origin stent. The severity of the lesion based on angiography alone is uncertain. The second angiographic panel shows a pressure wire in the distal renal artery placed via a 6F diagnostic catheter. The 0.014” pressure wire can be used with 4–6F diagnostic catheters. The simultaneous proximal and distal pressures in this case are equal. This is clearly not a hemodynamically important restenotic lesion.

References: 

1. Leimgruber PP, Roubin GS, Hollman J, et al. Restenosis after successful coronary angioplasty in patients with single-vessel disease. Circulation 1986;73(4):710–717.
2. Radermacher J, Chavan A, Bleck J, et al. Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. New England Journal of Medicine 2001;344(6):410–417.
3. Zeller T, Frank U, Muller C, et al. Predictors of improved renal function after percutaneous stent-supported angioplasty of severe atherosclerotic ostial renal artery stenosis. Circulation 2003;108 (18):2244–2249.
4. van Jaarsveld BC, Krijnen P, Pieterman H, et al. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. New England Journal of Medicine 2000;342(14): 1007–1014.
5. Feldman T, Laskey W. Alchemy in the cath lab: creating a gold standard for the evaluation of aortic stenosis. Cathet Cardiovasc Diagn 1998;44:14–15.
6. Fusman B, Faxon D, Feldman T. Hemodynamic rounds: Transvalvular pressure gradiant measurement. Cathet Cardiovasc Intervent 2001;53:553–561.
7. Feldman T, Carroll JD, Chiu YC. An improved catheter for crossing stenosed aortic valves. Cathet Cardiovasc Diag 1989;16:279–283.
8. Bonhoeffer P, Boudjemline Y, Saliba Z, et al. Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. Lancet 2000;356(9239): 1403–1405.

  • 1
  • 2
  • 3
  • 4
  • next ›
  • last »
Bookmark/Search this post with
  • Digg
  • LinkedIn
  • Reddit
  • Facebook Like
  • Google Plus One
  • Linkedin Share Button
  • Tweet Widget
image description image description Other Feature Articles

Post new comment

  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

More information about formatting options

Image CAPTCHA
Enter the characters shown in the image.
  • Advertise your Job Here
    For information on posting classified ads, please contact:
    Kimberly Sutkowski, Classified Sales Representative
    (800) 237-7285, ext. 205

Vascular Access: The VDM Clinician Blog

Anticoagulant Treatment of DVT and Preventing DVT-PE Made Easier

Frank J Criado MD FACS FSVM

Retrograde Crossing: When the Front Door Is Locked, Look for Another Way In!

Ajay U. Mhatre MD

Collecting More Data for Vascular Patients

Lawrence A. Garcia MD

A Road Less Traveled: Access in the Right Brachial Artery

Ajay U. Mhatre MD

Endovascular Options for Complex Abdominal Aortic Aneurysms

Robert S. Dieter MD RVT and Aravinda Nanjundappa MD RVT
more »

Vascular Newswire

  • Elixir Medical Receives CE Mark Approval for the Fully Bioresorbable DESolve Novolimus Eluting Coronary Scaffold System
    Wed, 05/15/13 - 10:12am
  • Reverse Medical Corporation Announces CE Mark and Initial Clinical Experience with the MVP Micro Vascular Plug for Peripheral Embolization
    Wed, 05/15/13 - 8:55am
  • St. Jude Medical Announces First Patient Enrollment in EnligHTN III Renal Denervation Study of Next-Generation EnligHTN System
    Wed, 05/15/13 - 8:52am
  • Decades of Improving Cholesterol Levels Abruptly Ended in 2008, PLOS ONE Study Finds
    Tue, 05/14/13 - 10:02am
more »

Clinical Events Calendar

  • New Frontiers in Endovascular Therapy
    Fri, 05/17/2013 - Sat, 05/18/2013
    Jacksonville, FL, United States
  • EuroPCR 2013
    Tue, 05/21/2013 - Fri, 05/24/2013
    Paris, France
  • European Society for Vascular Surgery European Vascular Trauma Workshop
    Mon, 05/27/2013 - Tue, 05/28/2013
    Sweden
more »

Poll

Drug-eluting balloons will have a major role in lower-extremity revascularization in the future.:
REVIEW OUR OTHER Cardiology BRANDS

Our other resources for healthcare professionals.

HMP Communications © 2013 HMP Communications

HMP Communications LLC (HMP) is the authoritative source for comprehensive information and education servicing healthcare professionals. HMP’s products include peer-reviewed and non-peer-reviewed medical journals, national tradeshows and conferences, online programs and customized clinical programs. HMP is a wholly owned subsidiary of HMP Communications Holdings LLC. ©2013 HMP Communications